(19)
(11) EP 4 561 574 A1

(12)

(43) Date of publication:
04.06.2025 Bulletin 2025/23

(21) Application number: 23754407.7

(22) Date of filing: 25.07.2023
(51) International Patent Classification (IPC): 
A61K 31/426(2006.01)
A61P 43/00(2006.01)
A61P 29/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/426; A61P 29/00; A61P 43/00
(86) International application number:
PCT/IB2023/057528
(87) International publication number:
WO 2024/023696 (01.02.2024 Gazette 2024/05)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 27.07.2022 US 202263369534 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • FARADY, Christopher John
    4002 Basel (CH)
  • GATLIK, Ewa
    4002 Basel (CH)
  • WALDRON-LYNCH, Frank Derrick
    Cambridge, Massachusetts 02139 (US)

(74) Representative: Mueller, Philippe 
Novartis Pharma AG Patent Department Lichtstrasse 35
4056 Basel
4056 Basel (CH)

   


(54) DOSING REGIMEN FOR A NLRP3 INHIBITOR